In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount...In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount importance. Sanhuang Xiexin Tang (SXT) and Baihu Tang (BHT) have emerged as prominent candidates for treating metabolic disorders. SXT combined with BHT plus Cangzhu (SBC) has been used clinically for Weihuochisheng obese patients. This retrospective analysis focused on assessing the anti-obesity effects of SBC in Weihuochisheng obese patients. We observed significant reductions in body weight and hepatic lipid content among obese patients following SBC treatment. To gain further insights, we investigated the effects and underlying mechanisms of SBC in HFD-fed mice. The results demonstrated that SBC treatment mitigated body weight gain and hepatic lipid accumulation in HFD-fed mice. Pharmacological network analysis suggested that SBC may affect lipid metabolism, mitochondria, inflammation, and apoptosis—a hypothesis supported by the hepatic transcriptomic analysis in HFD-fed mice treated with SBC. Notably, SBC treatment was associated with enhanced hepatic mitochondrial biogenesis and the inhibition of the c-Jun N-terminal kinase (JNK)/nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK)/NF-κB pathways. In conclusion, SBC treatment alleviates NAFLD in both obese patients and mouse models by improving lipid metabolism, potentially through enhancing mitochondrial biogenesis. These effects, in turn, ameliorate inflammation in hepatocytes.展开更多
文摘目的探究自拟二小汤(小青龙汤合小柴胡汤)治疗肺气虚寒型变应性鼻炎患者疗效及其对调节性T细胞(regulatory cells,Tregs)相关因子的作用。方法将64例患者随机分为观察组、对照组各32例。观察组应用自拟二小汤治疗,对照组采用氯雷他定片治疗。治疗28 d后,观察两组症状评分、血清中转化生长因子-β(transforming growth factor-β,TGF-β)、白介素10(interleukin-10,IL-10)、白细胞介素17(interleukin 17,IL-17)含量以及生活质量。结果治疗后,观察组的打喷嚏、鼻痒、鼻塞症状评分低于对照组(P<0.05);观察组血清中TGF-β、IL-10高于对照组(P<0.05),IL-17低于对照组(P<0.05);观察组鼻结膜炎生存量表(rhinoconjunctivitis quality of life scale,RQLQ评分)优于对照组(P<0.05)。结论自拟二小汤可以改善变应性鼻炎临床症状,提升患者血清中TGF-β、IL-10的含量,降低IL-17的含量,明显改善患者生活质量,效果全面优于氯雷他定片,值得临床进一步研究其机理及远期疗效。
基金supported by grants from the National Key R&D Program of China(2017YFA0105803)the National Natural Science Foundation of China(82270886,82070811)+2 种基金the Science and Technology Plan Project of Guangzhou City(202007040003,202201020497)the 5010 Clinical Research Projects of Sun Yat-Sen University(2015015)the Dengfeng Plan High-level Hospital Construction Opening Project of Foshan Fourth People's Hospital(FSSYKF-2020011 and FSSYKF-2020009)。
文摘In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid metabolism has gained paramount importance. Sanhuang Xiexin Tang (SXT) and Baihu Tang (BHT) have emerged as prominent candidates for treating metabolic disorders. SXT combined with BHT plus Cangzhu (SBC) has been used clinically for Weihuochisheng obese patients. This retrospective analysis focused on assessing the anti-obesity effects of SBC in Weihuochisheng obese patients. We observed significant reductions in body weight and hepatic lipid content among obese patients following SBC treatment. To gain further insights, we investigated the effects and underlying mechanisms of SBC in HFD-fed mice. The results demonstrated that SBC treatment mitigated body weight gain and hepatic lipid accumulation in HFD-fed mice. Pharmacological network analysis suggested that SBC may affect lipid metabolism, mitochondria, inflammation, and apoptosis—a hypothesis supported by the hepatic transcriptomic analysis in HFD-fed mice treated with SBC. Notably, SBC treatment was associated with enhanced hepatic mitochondrial biogenesis and the inhibition of the c-Jun N-terminal kinase (JNK)/nuclear factor-kappa B (NF-κB) and extracellular signal-regulated kinase (ERK)/NF-κB pathways. In conclusion, SBC treatment alleviates NAFLD in both obese patients and mouse models by improving lipid metabolism, potentially through enhancing mitochondrial biogenesis. These effects, in turn, ameliorate inflammation in hepatocytes.
